INTRODUCTION
Melanoma will afflict about 51,400 persons in the U.S. in 2001, with an incidence rate that is increasing about 3% per annum (1). While the disease is considered to be highly treatable upon early diagnosis, the prognosis upon onset of metastasis is dire, typified by a 13% five-year survival rate once distant malignancy has occurred. Aside from excision of the primary tumor, radiation therapy, chemotherapy, and immunotherapy are commonly used in an effort to control metastasis.
Photodynamic therapy (PDT) has proven successful for treatment of some forms of cancer (2) , but delivering the necessary ultraviolet or visible activating light through highly pigmented melanoma tumor tissue has proven difficult (3), precluding effective photodynamic destruction of the entire tumor. While many of the biological precursors to melanin produce a potent cytotoxic response when exposed to UV light (4) (5) (6) , and thus might be useful as endogenous photosensitizers, the absorbance of melanin normally precludes significant UV photoactivation within tumor tissue.
Non-linear activation (7) of synthetic melanin precursors has been demonstrated in vitro using near infrared (NIR) light from the titanium:sapphire laser (8) , producing a multiphoton-excited state equivalent to that occurring upon absorption of a UV photon. Such light should be capable of penetrating several millimeters into tumor tissue (9) , especially at wavelengths beyond 1000 nm, and might enable photodynamic treatment of tumors using eumelanin and pheomelanin precursors as naturally occurring photosensitizers. Linear absorption of such applied NIR light may also contribute to heating of melanin, and such heating could play an important role in therapeutic response (10, 11) . Finally, recent revival of interest in possible anti-tumor immunologic response upon PDT (12) (13) (14) (15) (16) (17) suggests that treatment of melanoma with NIR light might yield a useful immune response by unmasking antigenic materials sequestered within tumor tissues. those mice that exhibited recurrence were euthanized by CO 2 inhalation.
To allow elucidation of possible multiphoton and linear mechanisms in laser-tumor interaction, the Nd:YLF laser was operated in one of two modes: (1) mode-locked, yielding ca. 200 fs delivered pulse width at 120 MHz pulse repetition frequency; or (2) continuous wave, wherein cavity length was adjusted to preclude mode-locked pulse production. All other treatment parameters were identical, and mice were randomly assigned and treated with one of these operating modes. After centrifugation, the resultant cell-free supernatant was diluted (ca. 100-fold) into a 1.5 mL methacrylate cuvette (Fisher Scientific) , and its absorbance spectrum measured using a Genesys 2 UVvisible spectrometer (Thermo Spectronic, Inc., Rochester, NY, USA). An additional tissue specimen was homogenized in water and the resultant aqueous suspension diluted to obtain a spectrum illustrating melanin absorbance and tissue scatter.
Immunohistochemical assay. A cohort of laser treated mice (C57BL/6 mice with implanted B16- 
RESULTS
Gross and histologic response. Outcome in athymic nude mice. Treatment outcome for various treatments and tumor models is summarized in Table 1 ; data correspond to number of treated tumors exhibiting complete response (i.e., no recurrence). While all animals exhibited comparable acute response (i.e., blanching followed by localized eschar formation), long-term response rate for the pigmented tumor (B16-F10) was markedly greater than for the amelanotic tumor (M-3). Furthermore, no significant difference in response rate was noted for treatment with mode-locked vs. continuous wave laser radiation. Tables 2 and 3 . Three imunomodulators were examined: IL-2 (an immune system upregulator); IFN-ã; and IL-10 (an immune system down-regulator). Serum levels were found to remain constant (within the limits of detection of the tests) for all test conditions. In contrast, intralesional levels were markedly affected at 24-72 hours post treatment: IFN-ã and IL-2 levels were elevated at 24 hours, and IL-10 was elevated by 72 hours. These findings indicate that laser treatment produces a significant, localized immune response.
Tumor challenge data allows the significance of the immunohistochemical data of Tables 2 and 3 to be assessed, and is summarized in Table 4 . The observed tumor take rate for various challenge doses illustrates that once the initial tumor has been destroyed it cannot be re-established in immunocompetent mice (i.e., C57BL/6); in contrast, immune-deficient mice (i.e., athymic nudes) exhibit no such immune response following laser treatment.
DISCUSSION
Both M-3 (amelanotic) and B16-F10 (normally pigmented) tumor models were studied in an effort to elucidate the relevance of potential non-linear and linear photoactivation mechanisms. M-3 tumors produce normal levels of eumelanin and pheomelanin precursors, but are deficient in means to polymerize these precursors into melanin. Thus, the M-3 model provides a sensitive test for non-linear photoactivation, since the potentially phototoxic precursors are present (and capable of undergoing two-or three-photon excitation to a phototoxic state) while melanin levels (and hence potential for linear, hyperthermic effects upon linear absorbance of applied laser energy) are minimal. While the data in Table 1 show a greater response rate for laser activation of M-3 tumors using mode-locked radiation, these differences do not appear to be statistically significant. Furthermore, no acute gross or histologic differences were noted upon comparison of treatments under these two laser modes. Moreover, the results for B16-F10 tumors are markedly better, while again exhibiting no significant difference in clinical outcome, nor in acute gross or histologic outcome. Taken together, these results imply that thermal effects are the predominant mechanism Page 8 of 19
in tumor destruction.
The thermal data illustrated in Figure 2 shows that mean tumor temperature is increased into the 45-55EC temperature range during laser treatment, and that this increased temperature is maintained for >100 s. Niemz (19) shows that such combination of elevated temperature and duration yields irreversible hyperthermia, which is consistent with histologic observations of this study (i.e., tissue necrosis).
The maximum temperature appears to be much higher at the focus of the beam (i.e., $60EC), which, according to Niemz, is consistent with coagulation and possible denaturation. However, this highly elevated temperature is only experienced in a given volume of tumor tissue while the rapidly rastered focus is directed into that volume (i.e., high-speed measurements of tissue temperature illustrate that the maximum temperature only occurs in a give volume for 1 ms or less, and that this high-temperature zone tracks the motion of the beam across the tumor). Thus, it appears that a rapid spike in temperature (i.e., from the elevated average temperature to a maximum temperature then back to the average) may contribute to cellular photodisruption without wholesale denaturation of tumor proteins and other potentially antigenic materials. Such effects appear to be evidenced by acute tissue blanching (which becomes clearly evident within the first 10-20 s of laser treatment) as well as acute necrosis noted upon histologic examination.
Impulse heating, combined with sustained hyperthermic conditions, yields massive, acute coagulative necrosis of treated lesions yet appears to avoid complete destruction of antigenic materials present in or on destroyed cells; such destruction of antigens would occur upon sustained heating to temperatures in excess of 60EC, for example as occurs in laser-induced interstitial thermotherapy. In contrast, the present treatment regimen appears to yield localized, rapid release (i.e., unmasking) of large quantities of intact antigenic materials from the treated lesions. Although no systemic immune response is evident (as illustrated by the serum data in Table 2 , as well as lack of any other observable systemic effects, such as lethargy, fever, or edema proximal to the treated lesion), a potent localized response occurs within 24-h post-treatment (as evidenced by markedly increased levels of IFN-ã and IL-2 shown in Table   3 ). Presence of pro-inflammatory cytokines (i.e., IL-2) at 24-h, followed by appearance of antiPage 9 of 19 inflammatory cytokines (IL-10) within 72-h, is consistent with an acute, localized immune-system insult that begins to undergo resolution within this time frame. Contemporaneous formation of a localized eschar supports the assertion that the initial immune response is rapid, potent, and highly localized.
The relevance of this immune response is dramatically manifest by the tumor challenge data of Table 4 . Here, immunocompetent mice (i.e., C57BL/6) prove capable of rejecting massive challenge doses once they have received laser treatment of a primary lesion. In contrast, laser-treated immune-deficient mice (athymic nudes) are incapable of rejecting such challenge doses. The data in Table 4 suggest that onset of this anti-tumor immunity is rapid (within 1 week post-treatment) and permanent.
Efforts to demonstrate spontaneous remission of an untreated secondary tumor upon treatment of a similar contra-lateral primary tumor proved untenable, however, because the tumor models used in this study yield extremely virulent tumors characterized by massive, exponential rates of growth once they have 
